Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
25.40    -0.20 (-0.78%)
Bid:
25.40
Ask:
26.20
Spread: 0.80 (3.15%)
Market Cap: £109.29m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Director/PDMR Shareholding

21 Mar 2017 13:47

RNS Number : 0971A
EKF Diagnostics Holdings PLC
21 March 2017
Β 

Β 

Β 

EKF Diagnostics Holdings plc

("EKF", the "Company")

Β 

PDMR dealing

Β 

EKF Diagnostics Holdings plc (AIM: EKF) announces that on 21 March 2017, the Company was notified that Harwood Capital LLP ("Harwood") acquired 8,000,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.

Β 

Following the above transaction, which was completed on 20 March 2017 at a price of 19.5p pence per share, NAIT's interest is now in 98,000,000 Ordinary Shares, representing 21.12% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ("Oryx", whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.

Β 

The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 138,000,000 Ordinary Shares, representing 29.73% of the Company's issued share capital.

Β 

Β 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEOΒ 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Alex Price / Shaun Dobson / Alex Laughton-Scott

Walbrook PRΒ Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Β 

Harwood Capital LLP, as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT")

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

Β 

Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood Capital LLP and a director and shareholder in NAIT

Β 

b)

Β 

Initial notification /Amendment

Β 

Β 

Initial Notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Β 

EKF Diagnostics Holdings plc

b)

Β 

LEI

Β 

Β 

213800DXTF3EAUK1AR05

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

Β 

a)

Β 

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Β 

Ordinary shares of 1p each ("Ordinary Shares")

Β 

Β 

ISIN Code: GB0031509804

Β 

b)

Β 

Nature of the transaction

Β 

Β 

Acquisition of shares

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Price(s)

Β 

Volume(s)

19.5p

Β 

8,000,000

Β 

d)

Β 

Aggregated information

Β 

Β 

- Aggregated volume

Β 

Β 

- Price

Β 

Β 

n/a

e)

Β 

Date of the transaction

Β 

Β 

20 March 2017

f)

Β 

Place of the transaction

Β 

Β 

London Stock Exchange

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHBXGDXUSDBGRB
Date   Source Headline
16th Dec 20251:57 pmRNSShare Buyback
16th Dec 20257:00 amRNSExecutive Chair share purchase
8th Dec 20257:00 amRNSCancellation of Treasury Shares & TVR
24th Nov 202511:47 amRNSShare Buyback
19th Nov 20253:41 pmRNSShare Buyback
17th Nov 20252:12 pmRNSShare Buyback
4th Nov 20251:54 pmRNSTotal Voting Rights
3rd Nov 202510:19 amRNSShare Buyback
31st Oct 20251:02 pmRNSShare Buyback
30th Oct 202512:55 pmRNSShare Buyback
29th Oct 202510:59 amRNSShare Buyback
28th Oct 202511:00 amRNSShare Buyback
27th Oct 202510:25 amRNSShare Buyback
24th Oct 202511:10 amRNSShare Buyback
23rd Oct 202510:10 amRNSShare Buyback
21st Oct 20253:10 pmRNSShare Buyback & Extension of Buyback Programme
20th Oct 202512:24 pmRNSShare Buyback (Replacement)
20th Oct 202511:36 amRNSShare Buyback
17th Oct 20257:00 amRNSShare Buyback
15th Oct 202512:30 pmRNSShare Buyback
19th Sep 20254:25 pmRNSHolding(s) in Company
16th Sep 20257:15 amRNSLong Term Incentive Plan
16th Sep 20257:00 amRNSHalf-year Report
10th Sep 20257:00 amRNSNotice of interim results
26th Aug 20257:00 amRNSHematology contracts signed worth EUR 4.65m
28th Jul 20257:00 amRNSH1 2025 Trading Update
25th Jun 202512:00 pmRNSCancellation of Treasury Shares & TVR
17th Jun 20255:24 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSTotal Voting Rights
21st May 20257:00 amRNSAdditional Share Buyback Programme
20th May 20252:41 pmRNSResult of AGM and Voting Results
20th May 20257:00 amRNSAGM Statement
13th May 20257:00 amRNSShare Buyback & Completion of Share Buyback Prog.
9th May 20251:42 pmRNSShare Buyback
8th May 20259:11 amRNSShare Buyback
6th May 20253:55 pmRNSShare Buyback
29th Apr 20257:00 amRNSShare Buyback
28th Apr 20257:00 amRNSPosting of AR&A & Notice of AGM
9th Apr 20257:00 amRNSShare Buyback
8th Apr 20257:00 amRNSShare Buyback
7th Apr 20252:58 pmRNSShare Buyback
7th Apr 20257:00 amRNSShare Buyback
2nd Apr 20257:00 amRNSShare Buyback
1st Apr 20257:00 amRNSShare Buyback
26th Mar 20257:00 amRNSDirector/PDMR Shareholding
25th Mar 20257:00 amRNSAppointment of CEO
25th Mar 20257:00 amRNSFull year results
6th Mar 20257:00 amRNSNotice of Results & Investor Presentations
7th Feb 20253:04 pmRNSHolding(s) in Company
6th Feb 202511:34 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.